BrainsWay Announces Participation in a Virtual Fireside Chat at the Raymond James 2020 Human Health Innovation Conference


PATTERSON, N.J. and JERUSALEM, Israel, June 11, 2020 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the Raymond James Human Health Innovation Conference at 10:20 a.m. ET on Thursday, June 18, 2020.

About BrainsWay

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting and planning clinical trials of Deep TMS in other psychiatric, neurological, and addiction disorders.



Judy Huber

SVP and Chief Financial Officer



Bob Yedid

LifeSci Advisors